- Inicio
- Análisis de app
- ASDP Dermpath AUC
- ASDP Dermpath AUC Vs. iDermpath
ASDP Dermpath AUC vs iDermpath Uso & Estadísticas
Appropriate use criteria exist to help guide choosing testing for different diseases. The American Society of Dermatopathology's new Dermatopathology Appropriate Use Criteria app allows a systematic approach to reviewing tests for multiple conditions evaluated in Dermatopathology. The general audience includes Dermatopathologists, Pathologists, Dermatologists, or other referring physicians to allow easier access to the Dermatopathology Appropriate Use Criteria.
- App Store de Apple
- Gratis
- Medicina
Clasificación de tiendas
- -
iDermpath is an app developed for clients of Fleming Dermatopathology. It provides them with instant, wireless access to their pathology reports. New reports are announced with an audible signal (via the Apple push notification service). Old reports are also accessible. Pathology slips can be created in several ways, using the virtual keyboard, camera, and/or microphone. The fastest, and a completely paperless, method is to photograph the patient’s face sheet and dictate information such as biopsy site. Clinical photographs can easily be included with the slip for clinicopathologic correlation. Photos and audio clips remain attached to the case, and are accessible via the lab’s website. iDermpath is secure and HIPAA-compliant. It has a demo mode for those who are not yet clients of the lab.
- App Store de Apple
- Gratis
- Medicina
Clasificación de tiendas
- -
ASDP Dermpath AUC frente a iDermpath: comparación de la clasificación
Comparar la tendencia de clasificación de ASDP Dermpath AUC en los últimos 28 días con iDermpath
Rank
No hay datos disponibles
Comparación de las clasificaciones ASDP Dermpath AUC frente a iDermpath por países
Comparar la tendencia de clasificación de ASDP Dermpath AUC en los últimos 28 días con iDermpath
No hay datos para mostrar
Compara con cualquier sitio gracias a nuestra prueba gratuita
ASDP Dermpath AUC VS.
iDermpath
28iciembre d, 2024